Development and Feasibility Assessment of a Multimodal Digital Health Technology for Remote Monitoring of Symptoms in Myasthenia Gravis
These feasibility findings demonstrate that BioDigit MG is capable of reliable multimodal data collection and is acceptable to both patients and clinicians, supporting its potential for use in future larger scale validation studies.
Authors
- Gregory Barchard
- Amanda C. Guidon (ORCID: https://orcid.org/0000-0003-0843-2935)
- Ana Enriquez
- İlkay Yıldız Potter
- Abigail Lindsay
- Adonay S. Nunes (ORCID: https://orcid.org/0000-0002-8755-2240)
- Carl E. Stafstrom (ORCID: https://orcid.org/0000-0002-4432-2453)
- Ram Kinker Mishra (ORCID: https://orcid.org/0000-0001-9441-683X)
- Ashkan Vaziri
- Petra W. Duda
- Zoe Sheitman
Institutions
- Massachusetts General Hospital (US)
- BioSensics (United States) (US)
- UCB Pharma (United States) (US)
Publication Details
- Journal
- Digital Biomarkers
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1159/000549122
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Massachusetts General Hospital